Cargando…

MF59(®)-Adjuvanted H5N1 Vaccine Induces Immunologic Memory and Heterotypic Antibody Responses in Non-Elderly and Elderly Adults

BACKGROUND: Pathogenic avian influenza virus (H5N1) has the potential to cause a major global pandemic in humans. Safe and effective vaccines that induce immunologic memory and broad heterotypic response are needed. METHODS AND FINDINGS: Healthy adults aged 18–60 and >60 years (n = 313 and n = 17...

Descripción completa

Detalles Bibliográficos
Autores principales:	Banzhoff, Angelika, Gasparini, Roberto, Laghi-Pasini, Franco, Staniscia, Tommaso, Durando, Paolo, Montomoli, Emanuele, Capecchi, Pamela, di Giovanni, Pamela, Sticchi, Laura, Gentile, Chiara, Hilbert, Anke, Brauer, Volker, Tilman, Sandrine, Podda, Audino
Formato:	Texto
Lenguaje:	English
Publicado:	Public Library of Science 2009
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2634740/ https://www.ncbi.nlm.nih.gov/pubmed/19197383 http://dx.doi.org/10.1371/journal.pone.0004384

Ejemplares similares

Correction: MF59(®)-Adjuvanted H5N1 Vaccine Induces Immunologic Memory and Heterotypic Antibody Responses in Non-Elderly and Elderly Adults
por: Banzhoff, Angelika, et al.
Publicado: (2009)

MF59(®)‐adjuvanted vaccines for seasonal and pandemic influenza prophylaxis
por: Banzhoff, Angelika, et al.
Publicado: (2008)

Safety and immunogenicity of an MF59™-adjuvanted subunit influenza vaccine in elderly Chinese subjects
por: Li, Rongcheng, et al.
Publicado: (2008)

Safety of MF59-Adjuvanted Influenza Vaccination in the Elderly: Results of a Comparative Study of MF59-Adjuvanted Vaccine Versus Nonadjuvanted Influenza Vaccine in Northern Italy
por: Villa, Marco, et al.
Publicado: (2013)

Enhanced passive safety surveillance of the MF59-adjuvanted quadrivalent influenza vaccine in the elderly during the 2021/22 influenza season
por: Amicizia, Daniela, et al.
Publicado: (2023)

AS03- and MF59-Adjuvanted Influenza Vaccines in Children
por: Wilkins, Amanda L., et al.
Publicado: (2017)

Memory-like innate response to booster vaccination with MF-59 adjuvanted influenza vaccine in children
por: Kazmin, Dmitri, et al.
Publicado: (2023)

Fluad®-MF59®-Adjuvanted Influenza Vaccine in Older Adults
por: Tsai, Theodore F
Publicado: (2013)

Vaccine Efficacy of ALVAC-HIV and Bivalent Subtype C gp120/MF59 in Adults
por: Gray, Glenda E, et al.
Publicado: (2021)

Safety and Immunogenicity of MF59-Adjuvanted Cell Culture–Derived A/H5N1 Subunit Influenza Virus Vaccine: Dose-Finding Clinical Trials in Adults and the Elderly
por: Frey, Sharon E, et al.
Publicado: (2019)

The antibody landscapes following AS03 and MF59 adjuvanted H5N1 vaccination
por: Goll, Johannes B., et al.
Publicado: (2022)

Immunogenicity and protective efficacy in dogs of an MF59™-adjuvanted vaccine against recombinant canine/porcine coronavirus
por: Decaro, Nicola, et al.
Publicado: (2011)

Long QT Syndrome: An Emerging Role for Inflammation and Immunity
por: Lazzerini, Pietro Enea, et al.
Publicado: (2015)

Assessing QT interval in patients with autoimmune chronic inflammatory diseases: perils and pitfalls
por: Lazzerini, Pietro Enea, et al.
Publicado: (2016)

Vaccine adjuvant MF59 promotes the intranodal differentiation of antigen-loaded and activated monocyte-derived dendritic cells
por: Cioncada, Rossella, et al.
Publicado: (2017)

Immunogenicity of standard, high-dose, MF59-adjuvanted, and recombinant-HA seasonal influenza vaccination in older adults
por: Li, Athena P. Y., et al.
Publicado: (2021)

Antibody responses to intradermal or intramuscular MF59-adjuvanted influenza vaccines as evaluated in elderly institutionalized volunteers during a season of partial mismatching between vaccine and circulating A(H3N2) strains
por: Camilloni, Barbara, et al.
Publicado: (2014)

Commentary: Systemic effects of IL-17 in inflammatory arthritis
por: Lazzerini, Pietro Enea, et al.
Publicado: (2019)

Anti-Ro/SSA Antibodies and the Autoimmune Long-QT Syndrome
por: Lazzerini, Pietro Enea, et al.
Publicado: (2021)

Inflammatory cytokines and cardiac arrhythmias: the lesson from COVID-19
por: Lazzerini, Pietro Enea, et al.
Publicado: (2022)

MF management
por: Bose, Prithviraj, et al.
Publicado: (2019)

A Caprine Herpesvirus 1 Vaccine Adjuvanted with MF59™ Protects against Vaginal Infection and Interferes with the Establishment of Latency in Goats
por: Marinaro, Mariarosaria, et al.
Publicado: (2012)

Cytomegalovirus glycoprotein-B vaccine with MF59 adjuvant in transplant recipients: a phase 2 randomised placebo-controlled trial
por: Griffiths, Paul D, et al.
Publicado: (2011)

Intranasal Immunization Using Mannatide as a Novel Adjuvant for an Inactivated Influenza Vaccine and Its Adjuvant Effect Compared with MF59
por: Ren, Shu-Ting, et al.
Publicado: (2017)

A novel atheroprotective role of MF59-like adjuvant when co-administered with CETP vaccine in rabbit model of atherosclerosis
por: Aghebati, Tamara, et al.
Publicado: (2016)

Effectiveness of MF59™ Adjuvanted Influenza A(H1N1)pdm09 Vaccine in Risk Groups in the Netherlands
por: Wijnans, Leonoor, et al.
Publicado: (2013)

Relative Effectiveness of MF59 Adjuvanted Trivalent Influenza Vaccine vs Nonadjuvanted Vaccines During the 2019–2020 Influenza Season
por: Imran, Mahrukh, et al.
Publicado: (2022)

The cytomegalovirus gB/MF59 vaccine candidate induces antibodies against an antigenic domain controlling cell-to-cell spread
por: Gomes, A. C., et al.
Publicado: (2023)

Education in Vaccinology: An Important Tool for Strengthening Global Health
por: Lambert, Paul-Henri, et al.
Publicado: (2018)

Influenza A/H1N1 MF59 adjuvanted vaccine in pregnant women and adverse perinatal outcomes: multicentre study
por: Rubinstein, F, et al.
Publicado: (2013)

The Cost-Effectiveness of Vaccination of Older Adults with an MF59-Adjuvanted Quadrivalent Influenza Vaccine Compared to Other Available Quadrivalent Vaccines in Germany
por: Kohli, Michele A., et al.
Publicado: (2022)

Emerging Arrhythmic Risk of Autoimmune and Inflammatory Cardiac Channelopathies
por: Lazzerini, Pietro Enea, et al.
Publicado: (2018)

THE INTERSECTION OF ETHICS AND VULNERABLE ELDERS
por: Teaster, Pamela B, et al.
Publicado: (2019)

Effectiveness, immunogenicity, and safety of influenza vaccines with MF59 adjuvant in healthy people of different age groups: A systematic review and meta-analysis
por: Yang, Jing, et al.
Publicado: (2020)

Pistia Stratiotes and MF. Malayi
por: Fraser, G.
Publicado: (1938)

The acetabular roof reinforcement plate for the treatment of displaced acetabular fractures in the elderly: results in 59 patients
por: Krappinger, Dietmar, et al.
Publicado: (2021)

Epitope-Specific Humoral Responses to Human Cytomegalovirus Glycoprotein-B Vaccine With MF59: Anti-AD2 Levels Correlate With Protection From Viremia
por: Baraniak, Ilona, et al.
Publicado: (2018)

Phase 4, Post-Marketing Safety Surveillance of the MF59-Adjuvanted Influenza Vaccines FLUAD(®) and VANTAFLU(®) in South Korean Subjects Aged ≥65 Years
por: Yoo, Byung Wook, et al.
Publicado: (2018)

Letter to editor regarding the systematic review and meta‐analysis by Coleman et al. on the effectiveness of MF59‐adjuvanted seasonal influenza vaccine in older adults
por: Yin, J. Kevin, et al.
Publicado: (2021)

Immunogenicity and Safety of MF59-Adjuvanted Quadrivalent Influenza Vaccine Compared with a Nonadjuvanted, Quadrivalent Influenza Vaccine in Adults 50–64 Years of Age
por: Poder, Airi, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_qlp3qm63lod0cht319c3kfumpg